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Abstract: Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed
for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this
purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for
screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital.
Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended
in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or
DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results:
112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit
(43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95%
lack of social support). At the Fundació ACE’s Memory Clinic, 34 cases (87.2%) of mild cognitive
impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7
as a screening tool of cognitive impairment was AUROC = 0.739, p 0.024, CI 95% (0.609–0.825).
Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who
attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of
associated comorbidities was the main factor of declining referral.
Keywords: type 2 diabetes; mild cognitive impairment; Alzheimer’s disease
1. Introduction
The prevalence of dementia is rapidly increasing in developed countries due to social and
demographic changes. This trend is expected to worsen in the coming decades, with the number of
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cases possibly even tripling in the next 25 years. In fact, the World Health Organization has declared
dementia control a global health priority [1]. Although the effectiveness of treatment strategies is
limited, there is increasing evidence that early diagnosis leads to significant economic and social
benefits [2]. In addition, the disappointing results of clinical trials carried out in individuals with
dementia have generated the hypothesis that interventions have occurred too late in the disease process.
Probably the earlier we act, the better the chances of success [3]. Therefore, from the drug development
point of view, an early diagnosis is critically needed to identify optimal candidates for new clinical trials.
However, it is clear that in most health systems, dementia is underdiagnosed, and when diagnosis
occurs, it is typically at a relatively late stage in the disease process. Mild cognitive impairment (MCI)
represents a greater decline in cognition to that observed in normal cognitive decline associated with
age but not severe enough to cause significantly impaired daily function [4,5]. Generally, amnestic
MCI is characterized by a decreased ability to learn new information or retrieve stored information,
without affecting the basic activities of the daily living. Despite the fact that patients with MCI can
conduct a normal life, the important problem associated with MCI is that about 10–30% will progress
annually to dementia [6]. At present, there are no reliable indicators that could help us identify which
patients are at higher risk of progression to dementia.
Current epidemiological data show that patients with T2D have 2–3 times more risk of developing
Alzheimer’s disease (AD) than the non-diabetic population matched by age and others established
risk factors for developing dementia [5,6]. Furthermore, the diabetes duration, the poor glycemic
control and the frequency and severity of hypoglycemia are independent risk factors associated with
an accelerated cognitive decline in people with T2D [7–11].
Early diagnosis of MCI is important in T2D population for several reasons. First, the early
detection may be able to establish interventions aimed at slowing or even preventing progression to
dementia. In this regard, the use of drugs with no or only minimal hypoglycemia capacity is strongly
recommended [9]. In fact, the American Diabetes Association ADA clinical guidelines recommend
screening for early detection of cognitive impairment in adults older than 65 at the initial visit and
annual follow-ups as appropriate [10]. In addition, early diagnosis can allow the patient to participate
in research studies and support groups in the community if desired [11]
In recent years, several dementia prediction scores have been developed in the diabetic population,
such as the Diabetes Specific Dementia Risk Score (DSDRS) [12]. The variables collected are clinical and
do not require the patient’s presence. These variables are age, the presence of micro/macrovascular
disease, acute events related to diabetes, depression and the level of formal education of the patient.
After the score calculation, a result with predictive value of developing dementia in 10 years is obtained.
The applicability has not been widely extended.
On this basis, the objectives of the present study were (1) to evaluate the results of pre-screening for
MCI in the T2D population within the MOPEAD project in Spain and (2) to evaluate the applicability
of DSDRS as a screening tool for T2D patients with cognitive impairment.
2. Materials and Methods
This study is part of the MOPEAD project: Models of Patient Engagement for Alzheimer’s Disease.
It is a European Innovative Medicines Initiative (IMI2) Project-grant number 115985. The project
evaluated four models of patient engagement strategy (Runs) aimed to help identify individuals at risk
of AD in a multicenter setting (five countries were analyzed). The specific objectives were to (a) identify
individuals in the community with hidden cognitive impairment or individuals without cognitive
impairment at risk of AD; (b) promote cognitive wellbeing and healthy cognitive aging in the European
Union using AD Citizen Science, Open House and developing campaigns in primary and tertiary
care setting; (c) test innovative patient engagement models and generate clinical and demographic
data to evaluate the most efficient approaches; (d) develop common pre-screening methodologies
for practitioners.
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In each country, at least 100 patients were to be screened/model in order to refer at least 33 patients
to the memory clinic/model. The four different models were called “Runs”, as follows: (a) Run 1:
AD Citizen Science, on-line screening campaign; (b) Run 2: Open House campaign; (c) Run 3: Primary
care based patient engagement; (d) Run 4: Tertiary care based patient engagement. The extended
protocol was previously published and explained [13].
This paper focuses on a prospective observational study performed only in one center
(Vall d’Hebron University Hospital (HVH), Barcelona, Spain) as the leader of Run-4 (Tertiary care–based
patient engagement: Diabetologist setting) of the MOPEAD study. The study was approved by the
local ethics committee and conducted following the Strengthening the Reporting of Observational
Studies in Epidemiology guidelines. A total of 112 consecutive T2D patients fulfilling the inclusion
criteria were recruited from the pool of patients that attended the outpatient clinic. As per MOPEAD
protocol, the inclusion criteria were (a) age between 65–85 years; (b) T2D with duration > 5 years;
(c) functionally literate, without severe auditory and visual abnormalities; (d) written informed
consent; (e) clinical data available for the DSDRS calculation. Exclusion criteria were (a) other types
of diabetes; (b) previous diagnosis of AD, MCI or other types of dementia following the diagnostic
criteria of the NIA-AA [14]; (c) history of stroke; (d) history of unstable neurological or psychiatric
conditions that may affect cognition, including the presence of depression; (e) severe metabolic or
systemic disease such as unstable acute cardiovascular disease, renal failure with GFR < 30 mL/min/m2,
decompensated liver cirrhosis or liver failure, hypothyroidism untreated or vitamin B12 deficiency;
(f) drugs affecting cognitive status, for example, antipsychotics, opioids, long half-life benzodiazepines
like diazepam; (g) uncorrected severe sensory deficits (blindness, deafness).
All participants underwent a complete medical history, physical examination and
biochemical analysis.
DSDRS was calculated based on the clinical data and the medical history, as described by Exalto
et al. [12]. The score is the sum of several points that are assigned as follows: (a) age (60–64 years:
0, 65–69 years: 3, 70–74 years: 5; 75–79 years: 7; 80–84 years: 9; >85 years: 10), (b) associated
conditions (acute metabolic event: 2; macrovascular disease: 1; diabetic foot: 1; cerebrovascular
disease: 2; cardiovascular disease: 1; depression: 2), (c) education level (<12 years: 0; >12 years: −1).
The acute metabolic event was defined as severe hypoglycemia requiring assistance from another
person, hiperosmolar hyperglycemia or ketoacidosis. The complete score calculation is available in
Supplementary Material, Annex 2.
All the patients underwent the Minimental State Evaluation questionnaire (MMSE) [15], which was
administered by the same member of the health-care team for all patients. During the visit, all the
patients were asked up to three initial questions about their cognitive state: (1) “Do you feel that your
memory is getting worse?” (2) “How long have you been noticing it?” and (3) “Are you worried about
this alteration?” Additionally, a hypoglycemia survey was created for the MOPEAD protocol in order
to evaluate the presence, the number and severity of hypoglycemia (see Supplementary Material).
As per MOPEAD protocol, [13] those subjects having a MMSE score ≤ 27 or DSDRS ≥ 7 and positive
answer for ≥ 2 of the initial questions or DSDRS ≥ 10 were referred to the specialized memory clinic
(Fundació ACE, Barcelona, Spain) to complete the neuropsychological evaluation.
Statistical analysis: The categorical variables were expressed as a percentage. For the quantitative
variables, means and standard deviation are displayed if they follow a normal distribution, and those
that do not are displayed in median and range. To evaluate differences between groups Chi square test
was used for qualitative variables and Analysis of Variance (ANOVA); following this, DMS post-hoc
tests for quantitative variables were used. For variables that do not follow a normal distribution,
a nonparametric test was used to compare between groups (Kruskal–Wallis). To evaluate the correlation
between MMSE and DSDRS, the Pearson correlation test was performed. Significance was accepted at
p < 0.05. Regression was used to predict the Receiver Operating Characteristic (ROC) curves and the
chi-square test for comparison of ROC area. The statistical analyses were performed with the statistical
package SPSS version 21. Data of all the patients included in the study was used for descriptive
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statistics. Data from the patients that underwent a complete neuropsychological evaluation at the
memory clinic was used for correlations and regression analysis.
3. Results
A total of 112 consecutive T2D patients were recruited. The baseline characteristics are presented
in Table 1. Of all the enrolled patients, 82 (73.12%) fulfilled criteria for referral to the Fundació ACE’s
memory clinic for suspected cognitive impairment as per MOPEAD protocol.
Table 1. Baseline characteristics of the patients included in the study.
Meeting Criteria for
Referral to Memory
Clinic
Not Meeting Criteria
for Referral to Memory
Clinic
p
N (%) 82 (73.2%) 30 (26.7%) 0.001
Age (years) mean ± SD 74.77 ± 4.54 69.47 ± 3.44 0.02
Sex (women) n (%) 36 (43.9%) 13 (43.3%) 0.72
Education level (years) mean ± SD 6.87 ± 3.25 6.8 ± 4.73 0.46
BMI (kg/m2) mean ± SD 28.9 ± 5.1 32.0 ± 5.8 0.09
Smoker n (%) 72 (87.8%) 29 (96.6%) 0.06
Hypertension n (%) 77 (93.9%) 27 (90%) 0.63
Dyslipidemia n (%) 76 (92.6%) 29 (96.6%) 0.21
Obstructive sleep apnea n (%) 17 (20.7%) 8 (26.6%) 0.35
Ischemic heart disease n (%) 25 (30.4%) 5 (16.1%) 0.06
Peripheral arteriopathy n (%) 20 (24.3%) 4 (13.3%) 0.08
T2D duration (mean ± SD) 19.7 ± 9.8 17.5 ± 7.8 0.09
Insulin use n (%) 60 (73.1%) 18 (60%) 0.04
HbA1C (%) mean ± SD 7.7 ± 1.0 7.4 ± 0.8 0.43
Severe hypoglycemia (n) 6 0 NA
Diabetic retinopathy n (%) 53 (64.3%) 15 (50%) 0.28
Diabetic nephropathy n (%) 34 (41.4%) 13 (43.3%) 0.64
Diabetic polyneuropathy n (%) 27 (32.9%) 9 (30%) 0.53
MMSE mean ± SD 26.84 ± 2.01 28.8 ± 0.66 0.04
DSDRS mean ± SD 7.48 ± 2.2 4.63 ± 1.2 0.02
BMI: body mass index, T2D: type 2 diabetes, HbA1C: glycated hemoglobin A1C, MMSE: mini mental state evaluation,
DSDRS: diabetes specific dementia risk score.
Patients who met criteria for referring to memory clinic were older (median of 75 years (65–86)
versus 68 years (65–79), p = 0.02) and had a higher percentage of insulin treatment (73.1% versus
60%, p = 0.04) than patients who did not. In addition, a trend to present an increased burden of
cardiovascular disease and longer diabetes duration was also observed. Furthermore, as expected,
this group of patients presented lower MMSE (26.84 ± 2.01 versus 28.8 ± 0.66, p = 0.04) and higher
DSDRS scores (7.48 ± 2.2 versus 4.63 ± 1.2, p = 0.02), respectively. The detailed number of patients
that fulfilled the criteria for referral to the memory clinic (MMSE or DSDRS or both) are presented
in Supplementary Material, Annex 1. All the patients had at least two positive answers to the
initial questions.
Pearson correlation analyses showed inversely proportional relationship between MMSE and
DSDRS scores (r = −0.3640; CI (−0.414–−0.135) p < 0.05), as reflected in Figure 1.
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Figure 1. Correlation between DSDRS and MMSE scores. DSDRS: diabetes specific dementia risk score,
MMSE: Mini-Mental State Examination.
Of the 82 T2D patients meeting criteria of referral to memory clinic, 43 (52.4%) declined participation
in the second phase of the study due to associated comorbidities (21, 48.8%), lack of interest (16, 37.2%),
and absence of social support (6, 13.95%).
A total of 39 T2D were evaluated at the memory clinic and underwent a complete
neuropsychological assessment, as previously described [13], and 34 individuals (87.2%) received a
diagnosis of MCI, 3 (7.7%) of AD dementia and 2 (5.1%) of cognitively healthy. Table 2 reflects the
characteristics of these patients.
Table 2. Characteristics of the patients that were performed a complete neuropsychological evaluation
at the memory clinic.
Patients That Were Evaluated at the Memory Clinic
N 39
Race Caucasian
Age (years) median (min–max) 75 (68–84)
Education level < 9 years % 83.87
Sex (women) % 44.1
BMI (kg/ 2) mean ± SD 28.51 ± 4.01
Smoker (%) 54.83
Hypertension (%) 87.09
Dyslipidemia (%) 96
Ischemic heart disease (%) 25.80
Peripheral arteriopathy (%) 19.2
T2D duration (mean ± SD) years 19.1 ± 6.2
Insulin use% 67.74
HbA1C (%) mean ± SD 7.69 ± 0.76
Hypoglycemia (n) 64
Severe hypoglycemia (n) 6
Diabetic retinopathy (%) 54.83
Diabetic nephropathy (%) 38.70
Diabetic polyneuropathy (%) 22.58
MMSE (mean ± SD) 26.72 ± 2.14
Prevalence of MCI% 87.2
BMI: body mass index, MCI: mild cognitive impairment, MMSE: Mini-Mental State Examination, DSDRS: diabetes
specific dementia risk score.
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The regression logistic analysis revealed that MMSE and DSDRS scores were independent
predictors of the global cognitive impairment (MCI plus dementia), as reflected in Table 3.
Table 3. Independent predictors of cognitive function (MCI and dementia).
Coefficients a
Model
Unstardardized
Coefficients
Standardized
Coefficients
t Sig.
B ErrorEstándar Beta
1
(Constant) 6.147 1.205 5.102 0.000
Age −0.012 0.013 −0.121 −0.895 0.373
Insulin use 0.098 0.093 0.088 1.054 0.295
MMSE score −0.149 0.025 −0.528 −6.021 0.000
DSDRS score 0.063 0.027 0.306 2.310 0.023
a Dependent variable: Cognitive impairment. MMSE: Mini-Mental State Examination, DSDRS: diabetes specific
dementia risk score.
The predictive value of DSDRS ≥ 7 for the diagnosis of cognitive impairment was significant
AUC: 0.739, CI 95% (0.557–0.921), p < 0.024 (Figure 2).
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Figure 2. The ROC Curve for the MMSE and DSDRS as screening tools of cognitive impairment. MMSE:
Mini-Mental State Examination, DSDRS: diabetes specific dementia risk score.
The prediction capacity of combined MMSE and DSDRS for identifying subject with cognitive
impairment (MCI + dementia) was AUROC 0.902 (p 0.003, CI 95% (0.840–0.992)), significantly higher
(p 0.01) than MMSE (AUROC 0.785, p 0.007, CI 95% (0.814–0.948)) or DSDRS separately (AUROC 0.739,
p 0.024, CI 95% (0.609–0.825)) (Figure 2). No significant differences were seen between MMSE and
DSDRS separately. When insulin use was added to the model, the predictive value of the scores
combined was not changed (AUROC 0.904, p 0.001, CI95% (0.841–0.966)).
J. Clin. Med. 2020, 9, 2726 7 of 10
4. Discussion
In the present study, we found a high prevalence of cognitive impairment in the T2D patients older
than 65 who attended a third-level hospital, as part of the MOPEAD protocol in Spain. The suspected
diagnostic was confirmed in a reference memory clinic, and the clinical DSDRS score showed a
significant predictive value of cognitive impairment.
Although the DSDRS was not designed as a screening tool, our results suggest that it might
eventually be used as a complementary test for this purpose. Most of the developed countries are using
electronic medical history, thus making largely available reliable data in the medical records regarding
age, level of formal education, history of acute metabolic events, history of diabetic foot, history of
microvascular disease, history of cerebrovascular disease, history of cardiovascular disease, diagnosis
of depression. This information permits us to calculate DSDRS easily. An interesting proposal could
be the automatic calculation of the DSDRS score during or even before the patient’s visit. In this
regard, it could be extremely useful in clinical practice to receive a warning alarm in the event that the
diabetic patients present a score ≥ 7 in order to facilitate the identification of patients at higher risk
of presenting cognitive impairment. This strategy would allow selecting those patients in whom a
specific assessment of cognitive status should be implemented. However, specific studies to confirm
these preliminary results in larger cohorts are needed.
Unrecognized cognitive dysfunction can affect treatment adherence and diabetes self-management
resulting in poor glycemic control, an increased frequency of severe hypoglycemic episodes, and hospital
admissions [16]. Regarding hypoglycemia, two independent studies [17,18] showed that three or
more severe hypoglycemic episodes increased by almost two-fold the risk of dementia in T2D
patients. Despite of the role of hypoglycemia in the cognitive function, the frequency and severity of
hypoglycemia does not appear in current questionnaires for the evaluation of the risk of developing
dementia, and therefore, this crucial point should be tackled urgently. In order to fill this gap, we have
designed a hypoglycemia survey (see Supplementary Material) which was administered to all the
patients included in the present study. Notably, 6 patients who fulfilled the criteria of cognitive
impairment presented a history of severe hypoglycemia while no cognitively healthy participant
presented hypoglycemia.
In our study, the prevalence of MCI was 87.2% and for AD 7.7% in the group of patients that
attended the memory clinic. The prevalence of MCI in our sample was calculated based on the
39 patients that attended the memory clinic. However, it should be noted that more than half of the
patients that met criteria for referral to the memory clinic declined to continue the study, mainly due to
associated comorbidities and lack of interest. At present, the real prevalence of MCI in T2D patients
is unclear. Gao Y et al. reported a prevalence of MCI in T2D of 62.2% and AD 11.9% in Chinese
population [19] while Albai et al. [20] reported 42.03% MCI in T2D patients having a mean age of
63 years (range 57–71 y). The mean age of patients included in our study was of 75 years, all of them
were patients recruited from a tertiary care setting and most of them presented co-morbidities. These
factors should be taken into account when comparing the different series reported in the literature.
It should be noted that the neuropsychological battery and the data reported was not homogeneous
between the studies. Gao et al. and Albai et al. did not report data on the MMSE score or details on the
neuropsychological battery that was used. Additionally, Albai et al. did not report data on the education
level (one of the most important variables that influences cognitive function scoring), and both cited
studies lack data on the cardiovascular risk factors, complications of T2D and hypoglycemia.
Furthermore, the population included in our study was selected from the patients attended in a
tertiary setting, showing a high prevalence of MCI among this population, while the other two studies
included patients from general population. At present, there is no data regarding the prevalence of
cognitive impairment in T2D patients attended in a third level hospital, which represents a strength of
our study, even if we have preliminary results that need to be validated.
Patients attended in a third-level hospital usually are plurimedicated. They usually are prescribed
complex treatment regimes, some of them including insulin. As reflected by Table 3, almost 70% of
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the patients were using insulin. The importance of early detection of cognitive impairment in this
population comes from the need to adapt and adjust the specific treatment for T2D to the capacity
of management of the patient, in order to avoid worsening of T2D associated complications and to
limit possible errors in the administration of the medication, which may lead to hypoglycemia or other
unfavorable and potentially life-threatening events.
Several neuropsychological questionnaires have been proposed for the screening of cognitive
decline in T2D population [21]. However, the number of patients whose cognitive function needs
evaluating by the general practitioner or the endocrinologist/diabetologist is potentially enormous,
and a simpler and more cost-effective case-finding strategy to detect undiagnosed cognitive impairment
is needed. In our study, we showed that a simple score (DSDRS) calculated based on clinical variables
is useful as a screening tool for cognitive impairment (AUROC 0.739, p 0.024, CI 95% (0.609–0.825)) [12].
No differences were seen between the predictive values of MMSE and DSDRS separately as screening
tools for cognitive impairment. Nevertheless, as mentioned, the novelty of the DSDRS as a screening
tool is that it can be calculated using existing data in the medical history of the patient. Patients with
DSDRS ≥ 7 can be candidates for a more specific study of cognitive function. This score consists
of several clinical and demographic variables (age, gender, education, history of diabetic foot,
acute metabolic events, depression, microvascular disease, cardiovascular disease and cerebrovascular
disease). It should be noted that in our study, as per MOPEAD protocol, patients with stroke or
depression were excluded. We admit that in the real world, the DSDRS could be higher than the
obtained in the present study. Nevertheless, even with this bias, our results showed that the DSDRS
was a useful tool for identifying patients with diabetes at risk of dementia. The DSDRS was designed
as a risk score of dementia at 10 years, ranging from a 5% of dementia risk for those with the lowest
score up to a 73% risk for the highest score. The DSDRS was not designed as a screening tool, but it
might eventually be used as a complementary test for this purpose, in particular, if more detailed
information regarding diabetic complications (i.e., degree of diabetic retinopathy) and glycemic control
(i.e., hypoglycemic events and glycemic variability) was added. When the DSDRS score was added
to the MMSE, the predictive value for cognitive impairment significantly improved, supporting the
hypothesis that DSDRS can be an useful complementary screening tool (AUROC 0.902 (p 0.003, CI 95%
(0.840–0.992)), significantly higher than MMSE (AUROC 0.785, p 0.007, CI 95% (0.814–0.9648)) or
DSDRS separately (AUROC 0.739, p 0.024, CI 95% (0.609–0.825)).
One limitation of our study is the small sample size (as per protocol 100 patients/country [13])
and the fact that most of the patients that met criteria for referral to the memory clinic declined
further participation in the study due to associated comorbidities and lack of interest. This observation
deserves a comment: The study of cognitive status is not a current priority for the patients and health
care providers. This is a significant gap that should urgently be filled due to the importance of the
early detection of cognitive impairment and the implications in the management of the complex
treatment regimes.
Our results are preliminary, and a specific study to confirm that a refined DSDRS score could be a
useful complementary test for identifying T2D patients who should be referred to a memory clinic is
needed. If our results are confirmed in a further study, the DSDRS could be a screening tool that might
easily be implemented and automatically calculated by the electronic medical records of the patients,
as part of the daily clinical practice.
5. Conclusions
Diabetic patients in the tertiary care setting seem to have a high risk of developing cognitive
impairment, but they are usually patients with other severe diseases and complications. In consequence
in the case of these patients, the cognitive impairment is viewed as a secondary issue. Nevertheless,
early detection of AD is particularly important in this scenario because it could have a great impact on
diabetes control and self-management of complex regimes of treatment. Therefore, reliable screening
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tools and more education about cognitive impairment as a complication of type 2 diabetes are needed
both for patients and diabetes care providers.
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